Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04666740
Title A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Memorial Sloan Kettering Cancer Center
Indications

pancreatic adenocarcinoma

Therapies

Olaparib + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Memoral Sloan Kettering Monmouth (All protocol activities) Recruiting Middletown New Jersey 07748 United States Details
Memorial Sloan Kettering Bergen (All protocol activities) Recruiting Montvale New Jersey 07645 United States Details
Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (All protocol activities) Recruiting Commack New York 11725 United States Details
Memorial Sloan Kettering Westchester (All Protocol Activities) Recruiting Harrison New York 10604 United States Details
Memoral Sloan Kettering Basking Ridge (All protocol activitie) Recruiting New York New York 10065 United States Details
Memorial Sloan Kettering Cancer Center Recruiting New York New York 10065 United States Details
Memorial Sloan Kettering Nassau (All protocol activities) Recruiting Rockville Centre New York 11553 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field